Business Wire

iBASIS Integrates Cutting Edge Multi-Protocol Signaling Firewall of Security Expert jtendo for Global Cloud-Based Network Protection

19.9.2022 08:00:00 EEST | Business Wire | Press release

Share

iBASIS, the leading provider of communications solutions for operators and digital players worldwide, today announced the integration of the cutting-edge multi-protocol signaling firewall of telecom security expert jtendo to its Managed Cloud-Based Security Portfolio, iBASIS Security iQ360.

The increase in the number of network protocols (also covering 5G), technologies, and roaming traffic creates a greater complexity requiring advanced features for testing and cross-protocol correlation to monitor, analyze, detect, and prevent security breaches. The strategic partnership combines jtendo security audit experience, deep technical knowledge of telco protocols, and cross-protocol correlation expertise with iBASIS’ unique international and managed cloud-based skills, with dedicated security centers in Americas, Europe, and Asia.

"The growing threat trend around today’s telecom networks drives the need for innovative security management solutions that can adapt quickly to new threats," says Guillaume Klein, iBASIS Vice President, Product Management. "We are thrilled to collaborate with jtendo to achieve effective threat management and be able to leverage their unique auditing and multiprotocol expertise to raise the level of protection even further."

"We are very proud to partner with one of the largest international signaling, voice, and data networks and complement iBASIS’ 360-degree intelligence-based solution," adds Piotr Szymański, jtendo CEO. "Mobile operators are increasingly searching for threat management that continuously adapts to their ever-changing network landscape, offering a flexible managed solution hosted on the IPX network is an effective way to secure their signaling network as an ongoing process. We are always there to support our customers in keeping their network safe in all areas."

The iBASIS Security iQ360 platform provides MNOs with a high level of process automation to assess vulnerability and address security risks with advanced auditing. The solution relies on in-depth visibility, monitoring, and attack detection complemented with automatic rule updates against continuously evolving threats.

iBASIS and jtendo will be part of WAS#16, September 19-22, in Cape Town and will jointly present real-world security cases at Stand# L10.

ABOUT iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global, iBASIS is the first independent communications specialist, ranking third largest global wholesale voice operator, Top 3 LTE IPX vendor with 800+ LTE destinations.

iBASIS optimizes global connectivity, quality and security, so customers achieve high return on voice, SMS A2P messaging, mobile data, 5G roaming, IoT and cloud communications to be first in their respective markets. iBASIS today serves 1,000+ customers across 18 offices worldwide. For more information, please visit iBASIS.com.

ABOUT JTENDO
jtendo is the expert in telecom security, providing high-quality solutions and services to mobile network operators in more than 30 countries. jtendo secures networks against SS7, Diameter, and GTP vulnerabilities through a security suite headed by its proprietary SigWall (jtendo Signaling Firewall) solution.

With 90,000 TPS per single site in the largest SigWall installation, more than 1 million total TPS across all platforms and more than 100 million subscribers served by its platforms, jtendo is one of the world's most sought-after telecom and security specialists.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations
Melissa Coffman
26FIVE Tech Lab
+1 202 251 1793
iBASIS@26FIVE.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye